HYBRID EVENT: Join us in person in Orlando, Florida, USA or attend virtually from anywhere.

8th Edition of Global Conference on

Addiction Medicine, Behavioral Health and Psychiatry

October 21-23, 2027 | Orlando, Florida, USA

Naloxone

Naloxone

It is an opioid antagonist, which means that it inhibits or reverses the effects of opioid medications. It is mostly used to treat opioid drug overdoses due to its antagonistic properties. Naloxone binds to albumin at a rate of around 45%, although it also strongly interacts with other proteins. In order to stop the effects of opioid drugs, naloxone temporarily inhibits opioid receptors. Because naloxone cannot be used to get high, there is minimal risk that it will be taken without a prescription. There is no evidence that long-term naloxone use can have harmful physiological effects or cause dependence. Users of naloxone do not develop tolerance, and the drug is not known to have contributed to any overdose deaths. This condition primarily affects people in their 20s and 30s. The prodromal phase refers to the time before symptoms appear.

Committee Members
Speaker at Addiction Medicine, Behavioral Health and Psychiatry 2027 - Christopher Ashton

Christopher Ashton

TeDDs on Chapel, Centre for Recovery, Canada
Speaker at Addiction Medicine, Behavioral Health and Psychiatry 2027 - John J Giordano

John J Giordano

Life Enhancement Recovery Center, United States
Speaker at Addiction Medicine, Behavioral Health and Psychiatry 2027 - Sam Vaknin

Sam Vaknin

Commonwealth Institute of Advanced Professional Studies (CIAPS), United Kingdom

Submit your abstract Today

Whatsapp